(Q46341492)

21 December 2017

title

DIRECT new treatments for diabetic retinopathy (English)

1 reference

21 December 2017

author name string

Paul Mitchell

series ordinal

1

1 reference

21 December 2017

Tien Y Wong

series ordinal

2

1 reference

21 December 2017

language of work or name

English

0 references

publication date

25 September 2008

1 reference

21 December 2017

published in

The Lancet

1 reference

21 December 2017

volume

372

1 reference

21 December 2017

issue

9647

1 reference

21 December 2017

page(s)

1361-1363

1 reference

21 December 2017

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961413-0

7 January 2021

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961413-0

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961413-0

7 January 2021

Management of diabetic retinopathy: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961413-0

7 January 2021

Diabetic retinopathy and systemic vascular complications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961413-0

7 January 2021

Is diabetic retinopathy an independent risk factor for ischemic stroke?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961413-0

7 January 2021

Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961413-0

7 January 2021

Retinopathy and risk of congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961413-0

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961413-0

7 January 2021

Prospects for angiotensin receptor blockers in diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961413-0

7 January 2021

Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961413-0

7 January 2021

Appropriate Blood Pressure Control in type II diabetes (ABCD Trial): implications for complications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961413-0

7 January 2021

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961413-0

7 January 2021

Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961413-0

7 January 2021

The eye in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961413-0

7 January 2021

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961413-0

7 January 2021

Fenofibrate for diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961413-0

7 January 2021

10.1016/S0140-6736(08)61413-0

Identifiers

DOI

1 reference

21 December 2017

PubMed ID

18823657

1 reference

21 December 2017